CTOR
Citius Oncology, Inc.NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$78.09M
P/E Ratio
—
EPS
$-0.48
Beta
3.57
52W High
$6.19
52W Low
$0.49
50-Day MA
$0.79
200-Day MA
$1.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
35.59
PEG Ratio
—
About Citius Oncology, Inc.
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Fundamentals
| Revenue (TTM) | $5.61M |
| Gross Profit (TTM) | $4.49M |
| EBITDA | — |
| Operating Margin | -1716.00% |
| Return on Equity | -119.90% |
| Return on Assets | -28.30% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.38 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | 13.92 |
| EV/Revenue | 14.05 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $92.98M |
| Float | $14.88M |
| % Insiders | 79.64% |
| % Institutions | 15.32% |
Historical Volatility
HV 10-Day
92.44%
HV 20-Day
74.41%
HV 30-Day
88.46%
HV 60-Day
96.20%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($4.00 target)
1
Strong BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026